Loading…
avatar for Sheila A. Mikhail, JD, MBA

Sheila A. Mikhail, JD, MBA

Asklepios BioPharmaceutical, Inc.
Chief Executive Officer & Co-Founder
Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and is Chief Executive Officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio), a company she started in 2001. With $235 million in Series A funding, she built the company to more than 450 employees operating across five countries. Under her leadership, AskBio has advanced innovative gene therapy technology, including high-yield cell lines, an expansive capsid library, and synthetic promoters and DNA; advanced therapeutic programs into the clinic for Pompe disease, congestive heart failure, Limb-Girdle muscular dystrophy 2i/R9, Parkinson’s disease and Multiple system atrophy; and created a world-class gene therapy manufacturing operation, called Viralgen Vector Core, in San Sebastian, Spain. In December 2020, Ms. Mikhail led the negotiation of the $4 billion AskBio acquisition by Bayer AG.

Prior to AskBio, Ms. Mikhail served as CEO and co-founder of Bamboo Therapeutics, which in 20 months raised $50 million, advanced a therapeutic for Giant axonal neuropathy into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016 in a deal valued at $827 million. Prior to that, she was part of the management team at Chatham Therapeutics, which was acquired by Baxter in 2014. Ms. Mikhail practiced law for more than 15 years. During that time, she founded Life Sciences Law, a boutique law firm which serviced clients such as Bayer, Gilead, GSK, Sanofi and Aventis. Prior to moving to North Carolina in 2000, she practiced law with Ropes and Gray in Boston and was a management consultant with A.T. Kearney in Chicago.

Ms. Mikhail also co-founded the Columbus Children’s Foundation in 2017. The Foundation’s aim is to bring funding and scientific resources to the forefront so ultra-rare genetic disease research and development progresses at the same pace as other larger indications. This work can help accelerate access to gene therapy for children with these ultra-rare diseases.

She earned a JD with honors from Northwestern University, a finance MBA with honors from the University of Chicago, and a BS with highest honors from the University of Illinois at Urbana-Champaign. In 2021, Ms. Mikhail earned Ernst & Young’s Entrepreneur Of The Year® Southeast Award.
  • Timezone
  • Filter By Type
  • Executive Interview
  • Keynote
  • Networking Break
  • Panel Session
  • Virtual Happy Hour